Alnylam Pharmaceuticals Inc Bdr (A1LN34) Stock Price & News

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia

About Alnylam Pharmaceuticals Inc Bdr

CEO-

Employees2,5 k

Founded14 Jun. 2002

Headquarters-

Sector-

Websitealnylam.com

All values in USD	Sep. 2025	Des. 2025	Mrt. 2026	Jun. 2026
Revenue	1,25 mjd	1,10 mjd	1,17 mjd	1,29 mjd
Cost of goods sold	200,15 m	267,72 m	211,12 m	298,45 m
Cost of revenue	200,15 m	267,72 m	211,12 m	298,45 m
Research and development expenses	358,81 m	372,22 m	364,87 m	413,13 m
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	322,08 m	325,37 m	322,55 m	347,92 m
Operating expense	680,89 m	697,59 m	687,42 m	761,06 m
Total operating expenses	881,04 m	965,32 m	898,54 m	1,06 mjd
Operating income	367,98 m	131,72 m	268,64 m	231,44 m
Other non operating income	-74,15 m	92,98 m	-4,30 m	273,00 k
EBT including unusual items	238,97 m	161,14 m	221,65 m	177,81 m
EBT excluding unusual items	278,12 m	121,99 m	221,65 m	177,81 m
Income tax expense	-12,12 m	-25,28 m	15,66 m	13,31 m
Effective tax rate	-5,07%	-15,69%	7,07%	7,49%
Other operating expenses	-	-	-	-
Net income	251,08 m	186,42 m	205,99 m	164,49 m
Net profit margin	20,10%	16,99%	17,65%	12,74%
Earnings per share	2,90	1,25	1,99	1,84
Interest and investment income	28,68 m	26,63 m	26,60 m	28,14 m
Interest expense	-44,40 m	-129,34 m	-69,29 m	-82,05 m
Net interest expenses	-15,72 m	-102,71 m	-42,69 m	-53,91 m
Depreciation and amortization charges	-	-	-	-
EBITDA	381,78 m	145,22 m	282,19 m	245,34 m
Gain or loss from assets sale	-	-	-	-

Finance

Ask anything